Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tamiflu U.S. Labeling Adopts Japanese Warnings

This article was originally published in The Pink Sheet Daily

Executive Summary

Neuropsychiatric adverse event reports for Roche's antiviral jump in most recent review, prompting FDA staff to suggest a labeling change.

You may also be interested in...



FDA Recommends Precautionary Language On Neuropsychiatric Events For Tamiflu

Agency’s Pediatric Advisory Committee will also evaluate updated adverse event data from the 2006-2007 flu season for GSK’s Relenza.

FDA Recommends Precautionary Language On Neuropsychiatric Events For Tamiflu

Agency’s Pediatric Advisory Committee will also evaluate updated adverse event data from the 2006-2007 flu season for GSK’s Relenza.

Tamiflu Safety Will Get FDA Committee Review Nov. 27

The Pediatric Advisory Committee will evaluate reported neuropsychiatric and behavioral events from patients taking Roche’s influenza product.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel